That means blocking the interaction between PD‐1 and PD‐L1 by antibodies or any other methods will boost the immune response against cancer cells.[93] How to improve, widen, and predict the clinical response to anti‐PD‐1 therapy is a central theme in cancer immunology and immunotherapy. Here, CD274 is linked to cancer.